The Quality Lowdown: Quality Vision Falls Short At Various US and Indian Facilities
Court overrides stem cell clinic’s dismissal of drug GMPs, the US FDA upbraids drug makers for quality unit shortfalls, and a variety of snafus trigger drug recalls.
You may also be interested in...
Expert investigators found many problems at Ahmedabad plant, warning letter and Form 483 report show.
Agency demands review of invalidated out-of-specification findings as root causes of failures continue to elude Indian drugmaker at multiple facilities.
Emcure's Hinjwadi, India, plant should have investigated other more likely sources of contamination more thoroughly, the FDA says.